Regent Pacific Group Limited





(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575 19 May 2016

ANNOUNCEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

UPDATE ON COMMERCIALISATION OF PSD502®: APPROVAL OF TYPE IB VARIATION FOR REDUCED DOSE CAN

This announcement is made by Regent Pacific Group Limited ("**Regent Pacific**" or the "**Company**" and collectively with its subsidiaries, the "**Group**") in compliance with the disclosure requirements under Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**HK Listing Rules**") and the Inside Information Provisions (as defined in the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Regent Pacific is pleased to announce that on 17 May 2016 the European Medicines Agency ("**EMA**") approved the Company's Type IB variation for the reduced dose can (not less than 12 doses/can). The variation approval also includes the addition of Pharmaserve (North West) Ltd ("**PSNW**") as an alternative European Union ("**EU**") located manufacturer of PSD502® spray.

The approval of the variation will now enable the Company to progress with manufacturing activities with PSNW, which will allow the Company and Recordati S.p.A. ("**Recordati**") to commercially launch the reduced dose can in the UK around November 2016, with continental Europe following shortly thereafter. In addition, the

Regent Pacific Group Limited
8th Floor, Henley Building
5 Queen's Road Central
Hong Kong

Tel: (852) 2514 6111
Fax: (852) 2810 4792 | (852) 2509 0827
Email: info@regentpac.com
Website: www.regentpac.com

variation will trigger the €6 million (or approximately US$6.77 million or HK$52.81 million) variation payment from Recordati.

Under the terms of the Company's licence agreement with Recordati, a payment of up €10 million (or approximately US$11.28 million or HK$87.98 million) in total is payable upon first commercial sales of PSD502® in France, Germany, Italy, Spain and Portugal (being a payment of €2 million (or approximately US$2.26 million or HK$17.63 million) in respect of each of these countries).

Jamie Gibson, the Chief Executive Officer, commented: "We are extremely pleased that EUDRAC Ltd, our EU regulatory consultant, was able to obtain the Type IB variation approval from EMA before our deadline of 30 June 2016 and importantly, without the need to provide additional details to the agency. The variation approval represents the final step in the successful commercialisation of PSD502® in the EU and now we are looking forward to the successful commercial launch of PSD502® in the EU. The Company continues to focus on out-licensing in other major territories and on the submission for approval by the Food and Drug Administration within the USA. We look forward to giving updates to the market on both fronts in the near term."

About PSD502® and Premature Ejaculation

PSD502® is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. In two large, double blind, pivotal Phase III studies PSD502® showed a highly significant and clinically meaningful effect increasing mean intravaginal ejaculatory latency time at baseline from 0.5 minutes to 3.2 minutes. 87 per cent. of the patients in the studies were considered as responders with the product being well tolerated with no significant safety issues. PSD502® also showed positive effects across a wide range of other parameters including partner satisfaction.

Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 per cent. to 30 per cent. in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

The premature ejaculation market offers significant potential for development and growth given the absence of any widely approved pharmaceutical therapy with good patient acceptance. As a result an effective drug therapy for premature ejaculation may have a commercial potential comparable to erectile dysfunction drugs.

About Regent Pacific

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare and life sciences sectors. Its wholly-owned subsidiary, Plethora Solutions Holdings Plc, is a specialty pharmaceutical company whose core product PSD502® is the first EU approved topical prescription treatment for Premature Ejaculation, set to launch in EU in the latter half of 2016. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 18 years of financial reporting since its Initial Public Offering.

Note: Unless otherwise specified herein, (i) amounts dominated in € have been translated, for the purpose of illustration only, into US$ using the exchange rate of €1.00 = US$1.1281; and (ii) amounts dominated in US$ have been translated, for the purpose of illustration only, into HK$ using the exchange rate of US$1.00 = HK$7.80.

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Director

Directors of the Company:
James Mellon *(Co-Chairman)*[*]
Stephen Dattels *(Co-Chairman)*[*]
Jamie Gibson *(Chief Executive Officer)*
David Comba[#]
Julie Oates[#]
Mark Searle[#]
Jayne Sutcliffe[*]

[*] *Non-Executive Directors*
[#] *Independent Non-Executive Directors*

Hong Kong, 19 May 2016